• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Integra LifeSciences Holdings (IART) Prices 9.5% Notes, Is The Repair Story Still Undervalued?

    Simply Wall St·10/16/2026 20:23:07
    语音播报

    Integra LifeSciences Holdings (IART) has just priced a US$450 million offering of 9.5% senior secured notes due 2033, a refinancing move that reshapes the medical device maker’s capital structure.

    Recent trading has been choppy for Integra LifeSciences Holdings, with the share price at US$13.53 after a 1-day share price return of 2.69% and a 7-day share price return of 0.89%, while the 30-day share price return has fallen 13.77% and the 90-day share price return has declined 29.71% as investors absorb lower 2026 revenue guidance and a broader refinancing that now includes these 9.5% notes. At the same time, total shareholder return is down 7.39% over 1 year and has declined 64.28% over 3 years and 80.93% over 5 years. This signals that, despite some year-to-date share price momentum of 12.66%, sentiment around the long-term story has weakened as the business reshapes its balance sheet and earnings outlook.

    Scan beyond Integra LifeSciences Holdings and stress test your thesis against a curated set of sturdier balance sheets using our list of solid balance sheet and fundamentals (25 results).

    Integra LifeSciences Holdings is reshaping its balance sheet just as long term shareholders are still sitting on deep drawdowns. Is the recent refinancing a sign of business repair, or mostly a reset in sentiment before the valuation work begins?

    Most Popular Narrative: 49.9% Undervalued

    Against a last close of $13.53, the most followed narrative for Integra LifeSciences Holdings anchors fair value at $27.00, which frames the refinancing alongside a wider repair story in operations and cash generation.

    Analysts already factor in Integra LifeSciences Holdings finishing its Compliance Master Plan and stabilising operations. However, the reported reduction in remediation spending, several quarters without major supply upsets and ongoing transformation savings point to further room for structural cost efficiency gains that could still lift gross margin and earnings quality beyond what current models assume.

    See why 2 investors see Integra LifeSciences Holdings as 50% undervalued.

    Result: Fair Value of $27.00 (UNDERVALUED)

    Still, guidance slips or slower improvement in leverage and cash flow could quickly weaken confidence in the Integra LifeSciences Holdings repair story.

    Find out about the key risks to this Integra LifeSciences Holdings narrative.

    Next Steps

    Mixed sentiment around Integra LifeSciences Holdings does not need to leave you stuck on the sidelines. Move quickly, test the data, and weigh both the 3 key rewards and 1 important warning sign.

    Hunting For More Ideas Beyond Integra LifeSciences Holdings?

    If Integra LifeSciences Holdings has sharpened your focus on risk, return, and balance sheets, do not stop here. Fresh opportunities are only a few clicks away.

    Use the Simply Wall St Screener to pressure test your next move and avoid missing out on high quality ideas other investors are already reviewing.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.